Literature DB >> 24034707

Rapamycin augments human DC IL-12p70 and IL-27 secretion to promote allogeneic Type 1 polarization modulated by NK cells.

C Macedo1, H R Turnquist, M Castillo-Rama, A F Zahorchak, R Shapiro, A W Thomson, D Metes.   

Abstract

Mammalian target of rapamycin kinase inhibitor (mTORi) rapamycin (RAPA) use in transplantation can lead to inflammatory complications in some patients. Our goal was to better understand how mTORi-exposed human monocyte-derived dendritic cells (DC) stimulated with pro-inflammatory cytokines shape T cell allo-immunity. RAPA-conditioned-DC (RAPA-DC) displayed a more immature phenotype than untreated, control (CTRL)-DC. However, subsequent exposure of RAPA-DC to an inflammatory cytokine cocktail (ICC) plus IFN-γ induced a mature Type-1 promoting phenotype, consisting of elevated HLA-DR and co-stimulatory molecules, augmented IL-12p70 and IL-27 production, but decreased IL-10 secretion compared to CTRL-DC. Co-culture of mature (m)RAPA-DC with allogeneic peripheral blood mononuclear cells resulted in significantly increased Type-1 (IFN-γ) responses by T cells. Moreover, NK cells acted as innate modulators that conveyed activating cell-to-cell contact signals in addition to helper (IFN-γ) and/or regulatory (IL-10) soluble cytokines. We conclude that production of IL12-p70, IL-27 and low IL-10 by RAPA-DC allowed us to elucidate how these cytokines as well as NK-DC interaction shapes T cell allo-immunity. Thus, lack of inhibitory NK cell function during allo-specific T cell activation by human ICC + IFN-γ-stimulated RAPA-DC may represent an unwanted effector mechanism that may underlie RAPA-induced inflammatory events in transplant patients undergoing microbial infection or allograft rejection. © Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Dendritic cells; NK cells; human; rapamycin

Mesh:

Substances:

Year:  2013        PMID: 24034707      PMCID: PMC3842119          DOI: 10.1111/ajt.12351

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  52 in total

1.  mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS.

Authors:  Heth R Turnquist; Jon Cardinal; Camila Macedo; Brian R Rosborough; Tina L Sumpter; David A Geller; Diana Metes; Angus W Thomson
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

Review 2.  Paradoxical aspects of rapamycin immunobiology in transplantation.

Authors:  I R Ferrer; K Araki; M L Ford
Journal:  Am J Transplant       Date:  2011-04       Impact factor: 8.086

3.  Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy.

Authors:  S Brouard; I Puig-Pey; J-J Lozano; A Pallier; C Braud; M Giral; M Guillet; M C Londoño; F Oppenheimer; J M Campistol; J-P Soulillou; A Sanchez-Fueyo
Journal:  Am J Transplant       Date:  2010-12       Impact factor: 8.086

Review 4.  Innate or adaptive immunity? The example of natural killer cells.

Authors:  Eric Vivier; David H Raulet; Alessandro Moretta; Michael A Caligiuri; Laurence Zitvogel; Lewis L Lanier; Wayne M Yokoyama; Sophie Ugolini
Journal:  Science       Date:  2011-01-07       Impact factor: 47.728

Review 5.  Natural innate and adaptive immunity to cancer.

Authors:  Matthew D Vesely; Michael H Kershaw; Robert D Schreiber; Mark J Smyth
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

Review 6.  The regulation of IL-10 production by immune cells.

Authors:  Margarida Saraiva; Anne O'Garra
Journal:  Nat Rev Immunol       Date:  2010-02-15       Impact factor: 53.106

7.  A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation.

Authors:  Michael Haidinger; Marko Poglitsch; Rene Geyeregger; Sudhir Kasturi; Maximilian Zeyda; Gerhard J Zlabinger; Bali Pulendran; Walter H Hörl; Marcus D Säemann; Thomas Weichhart
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

8.  Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses.

Authors:  Ivana R Ferrer; Maylene E Wagener; Jennifer M Robertson; Alexa P Turner; Koichi Araki; Rafi Ahmed; Allan D Kirk; Christian P Larsen; Mandy L Ford
Journal:  J Immunol       Date:  2010-07-14       Impact factor: 5.422

9.  The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.

Authors:  Greg M Delgoffe; Kristen N Pollizzi; Adam T Waickman; Emily Heikamp; David J Meyers; Maureen R Horton; Bo Xiao; Paul F Worley; Jonathan D Powell
Journal:  Nat Immunol       Date:  2011-02-27       Impact factor: 25.606

10.  Comparative study of clinical grade human tolerogenic dendritic cells.

Authors:  M Naranjo-Gómez; D Raïch-Regué; C Oñate; L Grau-López; C Ramo-Tello; R Pujol-Borrell; E Martínez-Cáceres; Francesc E Borràs
Journal:  J Transl Med       Date:  2011-06-09       Impact factor: 5.531

View more
  14 in total

1.  mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In Vivo.

Authors:  Dàlia Raïch-Regué; Brian R Rosborough; Alicia R Watson; Mandy J McGeachy; Hēth R Turnquist; Angus W Thomson
Journal:  J Immunol       Date:  2015-04-03       Impact factor: 5.422

2.  Reparixin, a CXCR1/2 inhibitor in islet allotransplantation.

Authors:  Rena L Pawlick; John Wink; Andrew R Pepper; Antonio Bruni; Nasser Abualhassen; Yasmin Rafiei; Boris Gala-Lopez; Mariusz Bral; A M James Shapiro
Journal:  Islets       Date:  2016-06-21       Impact factor: 2.694

Review 3.  Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells.

Authors:  D P McCarthy; J Bryant; J P Galvin; S D Miller; X Luo
Journal:  Am J Transplant       Date:  2015-03-23       Impact factor: 8.086

4.  High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation.

Authors:  Alan F Zahorchak; Camila Macedo; David E Hamm; Lisa H Butterfield; Diana M Metes; Angus W Thomson
Journal:  Cell Immunol       Date:  2017-09-14       Impact factor: 4.868

Review 5.  Regulation of innate immune cell function by mTOR.

Authors:  Thomas Weichhart; Markus Hengstschläger; Monika Linke
Journal:  Nat Rev Immunol       Date:  2015-10       Impact factor: 53.106

6.  Glucose represses dendritic cell-induced T cell responses.

Authors:  Simon J Lawless; Nidhi Kedia-Mehta; Jessica F Walls; Ryan McGarrigle; Orla Convery; Linda V Sinclair; Maria N Navarro; James Murray; David K Finlay
Journal:  Nat Commun       Date:  2017-05-30       Impact factor: 14.919

Review 7.  mTOR-Mediated Regulation of Dendritic Cell Differentiation and Function.

Authors:  Nyamdelger Sukhbaatar; Markus Hengstschläger; Thomas Weichhart
Journal:  Trends Immunol       Date:  2016-09-07       Impact factor: 16.687

8.  Rapamycin Alternatively Modifies Mitochondrial Dynamics in Dendritic Cells to Reduce Kidney Ischemic Reperfusion Injury.

Authors:  Maria Namwanje; Bijay Bisunke; Thomas V Rousselle; Gene G Lamanilao; Venkatadri S Sunder; Elizabeth C Patterson; Canan Kuscu; Cem Kuscu; Daniel Maluf; Manjari Kiran; Valeria Mas; James D Eason; Amandeep Bajwa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

9.  Non-autophagy Role of Atg5 and NBR1 in Unconventional Secretion of IL-12 Prevents Gut Dysbiosis and Inflammation.

Authors:  Seth D Merkley; Samuel M Goodfellow; Yan Guo; Zoe E R Wilton; Janie R Byrum; Kurt C Schwalm; Darrell L Dinwiddie; Rama R Gullapalli; Vojo Deretic; Anthony Jimenez Hernandez; Steven B Bradfute; Julie G In; Eliseo F Castillo
Journal:  J Crohns Colitis       Date:  2022-02-23       Impact factor: 10.020

10.  Rapamycin Synergizes with Cisplatin in Antiendometrial Cancer Activation by Improving IL-27-Stimulated Cytotoxicity of NK Cells.

Authors:  Wen-Jie Zhou; Kai-Kai Chang; Ke Wu; Hui-Li Yang; Jie Mei; Feng Xie; Da-Jin Li; Ming-Qing Li
Journal:  Neoplasia       Date:  2017-12-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.